{"id":"ray1225","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"RAY1225 targets FGFR-driven oncogenic signaling in tumors with FGFR alterations. By inhibiting FGFR kinase activity, the drug blocks downstream proliferation and survival signals in cancer cells dependent on aberrant FGFR signaling, particularly in solid tumors with FGFR mutations or fusions.","oneSentence":"RAY1225 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:16.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-altered solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07460284","phase":"PHASE1","title":"A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2026-03-15","conditions":"Basic Science","enrollment":8},{"nctId":"NCT05835752","phase":"PHASE1","title":"The Safety, Tolerability and Pharmacokinetic Study of RAY1225","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2023-05-18","conditions":"Obese, Healthy","enrollment":68},{"nctId":"NCT07362030","phase":"PHASE1","title":"Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-04-14","conditions":"Obesity","enrollment":32},{"nctId":"NCT07139548","phase":"PHASE3","title":"A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-08-31","conditions":"T2DM","enrollment":600},{"nctId":"NCT07139535","phase":"PHASE3","title":"A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-08-31","conditions":"T2DM","enrollment":350},{"nctId":"NCT06254274","phase":"PHASE2","title":"A Study of RAY1225 in Participants With Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2024-02-26","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":210},{"nctId":"NCT06893016","phase":"PHASE3","title":"Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2025-06-15","conditions":"Obesity","enrollment":640},{"nctId":"NCT06254261","phase":"PHASE2","title":"A Study of RAY1225 in Participants With Obesity","status":"RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2024-02-21","conditions":"Obesity","enrollment":270},{"nctId":"NCT06577428","phase":"PHASE1","title":"A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2024-07-30","conditions":"Healthy","enrollment":48},{"nctId":"NCT06577415","phase":"PHASE1","title":"A Study of RAY1225 in Participants With Impaired Liver Function","status":"RECRUITING","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2024-08-26","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT06613763","phase":"PHASE1","title":"A Study of RAY1225 in Participants With Impaired Kidney Function","status":"COMPLETED","sponsor":"Guangdong Raynovent Biotech Co., Ltd","startDate":"2024-09-11","conditions":"Kidney Impairment","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RAY1225","genericName":"RAY1225","companyName":"Guangdong Raynovent Biotech Co., Ltd","companyId":"guangdong-raynovent-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RAY1225 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling pathways. Used for FGFR-altered solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}